A Phase 1 interventional study of BMS-663068 and Oral Contraceptive in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 2 sites in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-27.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label, single sequence, 4-cycle, 4-treatment, drug-drug interaction (DDI) study in healthy female subjects on oral contraceptives (OC). There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-663068 with OC will not affect the pharmacokinetics (PK) of either ethinyl estradiol (EE) or norethindrone (NE).
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 26 is below the median of 113 across 1,304 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined exclusion criteria could apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A/Cycle 1: OC containing EE and progestin taken by mouth. Treatment B/Cycle 2: OC containing EE and progestin taken by mouth. Treatment C/Cycle 3: Loestrin 1.5/30 taken by mouth. Treatment D/Cycle 4: Loestrin 1.5/30 (alone) and Loestrin 1.5/30 with BMS-663068 taken by mouth.
Drug: BMS-663068 · Drug: Oral Contraceptive · Drug: Loestrin 1.5/30
Investigational product
Subject's existing combination OC tablet containing EE and progestin
OC containing EE and norethindrone acetate (NEA)
Also known as: Junel, Microgestin 1.5/30
Pharmacokinetic parameter Cmax
Pharmacokinetic parameter includes: maximal observed concentration (Cmax) for EE and NE.
Time frame: From Day 21 of Treatment C/Cycle 3 to Day 21 of Treatment D/Cycle 4
Pharmacokinetic parameter AUC TAU
Pharmacokinetic parameter includes: area under the concentration-time curve in one dosing interval (AUC(TAU)) for EE and NE.
Time frame: From Day 21 of Treatment C/Cycle 3 to Day 21 of Treatment D/Cycle 4
Clinical Safety as Measured by Adverse Event Monitoring.
Adverse event monitoring
Time frame: From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)
Clinical Safety as Measured by the Collection of Vital Signs.
Vital signs assessments
Time frame: From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)
Clinical Safety as Measured by the Collection of Electrocardiograms (ECGs).
12-lead ECGs
Time frame: From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)
Clinical Safety as measured by Physical Examination.
Physical examinations
Time frame: From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)
Clinical Safety as Measured by Clinical Laboratory Evaluations.
clinical chemistry, hematology, and urinalysis.
Time frame: From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)
Pharmacokinetic Parameter
Pharmacokinetic parameter: -time of maximum observed concentration (Tmax) for EE and NE.
Time frame: From Day 21 of Treatment C/Cycle 3 to Day 21 of Treatment D/Cycle 4
Ran from Jul 2015 to primary completion in Jan 2016, 6 months.
Of 51 industry-sponsored phase 1 interventional studies under Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's 6 months is close to that.
Counting every sponsor, half of 78 studies reached it within 10 months; a quarter within 3 and three quarters within 20.
Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fostemsavir